419 related articles for article (PubMed ID: 28609766)
1. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
3. The JAK2 V617F mutation in patients with cerebral venous thrombosis.
Passamonti SM; Biguzzi E; Cazzola M; Franchi F; Gianniello F; Bucciarelli P; Pietra D; Mannucci PM; Martinelli I
J Thromb Haemost; 2012 Jun; 10(6):998-1003. PubMed ID: 22469236
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
[TBL] [Abstract][Full Text] [Related]
6. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
8. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
[No Abstract] [Full Text] [Related]
9. Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
Levraut M; Legros L; Drappier C; Béné MC; Queyrel V; Raynaud S; Martis N
J Thromb Thrombolysis; 2020 Nov; 50(4):995-1003. PubMed ID: 32266587
[TBL] [Abstract][Full Text] [Related]
10. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
11. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
12. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
14. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder.
Bellucci S; Cassinat B; Bonnin N; Marzac C; Crassard I
Thromb Haemost; 2008 Jun; 99(6):1119-20. PubMed ID: 18521518
[No Abstract] [Full Text] [Related]
15. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
Owens CD
J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
[TBL] [Abstract][Full Text] [Related]
16. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.
Colaizzo D; Tiscia GL; Bafunno V; Amitrano L; Vergura P; Lupone MR; Grandone E; Guardascione MA; Margaglione M
Thromb Res; 2011 Sep; 128(3):233-6. PubMed ID: 21497883
[TBL] [Abstract][Full Text] [Related]
17. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
[TBL] [Abstract][Full Text] [Related]
18. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutation and thrombosis.
Austin SK; Lambert JR
Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
